Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865709 · ClinicalTrials.gov registry record · Phase 2
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
NCT00865709 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 198 participants.
The verdict
NCT00865709, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
Study Summary
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- DRUG Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865709
The ClinicalTrials.gov registry entry for NCT00865709 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) is the first listed.
NCT00865709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865709 about?
NCT00865709 is a clinical study titled "Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects". To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
What is the current status of trial NCT00865709?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2009-03. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00865709?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) (DRUG), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) (DRUG).
Who is sponsoring clinical trial NCT00865709?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.